ATP1B1: A Target for Therapies for Cell Signaling and Disease

Target Name: ATP1B1

NCBI ID: G481

ATP1B1

ATP1B1: A Target for Therapies for Cell Signaling and Disease

ATP1B1 (Adenosinetriphosphatase) is a protein that plays a crucial role in the regulation of cell signaling pathways. It is a key enzyme in the adenylyl cyclic trisphosphate (ACTP) system, which is responsible for storing and releasing energy in the form of ATP. Malfunctioning ATP1B1 has been implicated in a number of diseases, including heart failure, cancer, and neurodegenerative disorders. As a result, targeting ATP1B1 has become an attractive research focus for scientists.

ATP is a ubiquitous molecule that plays a central role in cellular signaling. It is the energy currency of the cell and is involved in nearly all cellular processes that require energy. When a cell needs to initiate a signaling cascade, it produces ATP, which is then rapidly broken down to release energy. This process is regulated by a complex network of enzymes, including ATP1B1.

ATP1B1 is a key enzyme in the ACTP system, which is responsible for generating ATP by converting ADP (adenylate) to ATP. The ACTP system is a highly conserved family of enzymes that includes several similar enzymes, including ATP1A, ATP1B, ATP1C, and ATP1E. These enzymes share a common catalytic core and share a similar mechanism of action, but they differ in their substrate specificity and other aspects of their structure and function.

ATP1B1 is a 21-kDa protein that is expressed in most tissues and cells. It is highly conserved, with a calculated pI of 12.9 and a predicted localization in the cytoplasm. ATP1B1 is a monomer that consists of a catalytic core and a peripheral region that includes a transmembrane region and a nucleotide-binding domain. The catalytic core of ATP1B1 consists of a unique 尾-sheet structure that is held together by a disulfide bond.

The peripheral region of ATP1B1 includes a transmembrane region and a nucleotide-binding domain. The transmembrane region is involved in the regulation of ATP1B1's activity and includes a putative IP3 (inositol-dependent phosphate) sensor that is involved in the regulation of ATP1B1's activity. The nucleotide-binding domain is responsible for binding to the nucleotides that are added to the growing chain of ATP.

Malfunctioning ATP1B1 has been implicated in a number of diseases. For example, it has been shown to be involved in the regulation of muscle contractions and to play a role in the development of cancer. In addition, malfunctioning ATP1B1 has been linked to a number of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

Targeting ATP1B1 has become an attractive research focus in recent years, as it has the potential to be a drug target or biomarker. Several studies have identified potential drug targets for ATP1B1, including those that target the ACTP system as a whole and those that target specific components of the enzyme.

One approach to targeting ATP1B1 is to block its catalytic activity by inhibiting the addition of nucleotides to the growing chain of ATP. This can be done using a variety of techniques, including inhibition of ATP1B1 by small molecule inhibitors or by using antibodies that specifically bind to ATP1B1. In addition, several researchers have used RNA interference (RNAi) to knockdown ATP1B1 gene expression in order to reduce the amount of ATP produced and to decrease the activity of the enzyme.

Another approach to

Protein Name: ATPase Na+/K+ Transporting Subunit Beta 1

Functions: This is the non-catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of Na(+) and K(+) ions across the plasma membrane. The beta subunit regulates, through assembly of alpha/beta heterodimers, the number of sodium pumps transported to the plasma membrane (PubMed:19694409). Plays a role in innate immunity by enhancing virus-triggered induction of interferons (IFNs) and interferon stimulated genes (ISGs). Mechanistically, enhances the ubiquitination of TRAF3 and TRAF6 as well as the phosphorylation of TAK1 and TBK1 (PubMed:34011520)

The "ATP1B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP1B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets